RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis-Reference-Cited by-同舟云学术

RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis

Published:2019-06-07 Issue:13 Volume:60 Page:3181-3187
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Zeidan Amer M.¹²,Zhu Weiwei²³,Stahl Maximilian¹²⁴,Wang Rong²³,Huntington Scott F.¹²,Giri Smith¹²,Podoltsev Nikolai A.¹²,Gore Steven D.¹²,Ma Xiaomei²³,Davidoff Amy J.²⁵

Affiliation:

1. Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT, USA;

2. Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA;

3. Department of Chronic Disease Epidemiology, School of Public Health, Yale University, New Haven, CT, USA;

4. Department of Medicine, Section of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA;

5. Department of Health Policy and Management, School of Public Health, Yale University, New Haven, CT, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2019.1622700

Reference24 articles.

1. How we treat lower-risk myelodysplastic syndromes

2. Association between Transfusion Status and Overall Survival in Patients with Myelodysplastic Syndromes: A Systematic Literature Review and Meta-Analysis

3. Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes

4. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents

5. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of Anemia in Lower-Risk Myelodysplastic Syndrome;Current Treatment Options in Oncology;2024-05-30

2. Beyond the horizon: emerging therapeutic approaches in myelodysplastic neoplasms;Experimental Hematology;2024-02

3. Time to first transfusion in lower-risk patients with myelodysplastic neoplasia (MDS) is another prognostic factor of survival;Leukemia & Lymphoma;2023-05-31

4. Can Lower-Risk MDS Achieve High Reward with Hypomethylating Agent Therapy?;NEJM Evidence;2022-09-27

5. The impact of race and ethnicity on outcomes of patients with myelodysplastic syndromes: a population-based analysis;Leukemia & Lymphoma;2022-02-08